InsidersTradesSigma
Follow the FULCRUM THERAPEUTICS INC stock price and the full management transaction log of the company, a listed issuer based in United States. Shares trade on US US, under the supervision of SEC (Form 4). Market capitalisation: €233.2m. The latest transaction was reported on 26 June 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: ALAN EZEKOWITZ. All data is openly available.
Analysts rate FULCRUM THERAPEUTICS INC Hold (neutral), based on 6 analysts. Average price target: US$5.83.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
1 of 1 declaration
FULCRUM THERAPEUTICS INC is a biopharmaceutical company focused on developing treatments for genetic diseases. It employs innovative approaches to target specific disease mechanisms.